Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) was the target of a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 294,700 shares, a drop of 9.6% from the August 31st total of 326,000 shares. Based on an average trading volume of 5,800 shares, the days-to-cover ratio is presently 50.8 days.
HKMPF has been the topic of a number of research reports. Morgan Stanley lowered shares of Hikma Pharmaceuticals from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, September 22nd. Barclays raised shares of Hikma Pharmaceuticals from an “equal weight” rating to an “overweight” rating in a report on Friday, September 4th. ValuEngine lowered shares of Hikma Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, June 8th. Goldman Sachs Group raised shares of Hikma Pharmaceuticals from a “neutral” rating to a “buy” rating in a report on Tuesday, September 8th. Finally, Zacks Investment Research raised shares of Hikma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a report on Wednesday, June 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Hikma Pharmaceuticals presently has an average rating of “Hold” and an average target price of $32.00.
HKMPF stock traded up $1.72 during trading on Friday, hitting $34.45. 121 shares of the company’s stock traded hands, compared to its average volume of 2,384. The firm has a market capitalization of $8.35 billion, a P/E ratio of 21.82 and a beta of 0.49. The business has a fifty day simple moving average of $32.44 and a two-hundred day simple moving average of $29.11. The company has a quick ratio of 0.87, a current ratio of 1.26 and a debt-to-equity ratio of 0.05. Hikma Pharmaceuticals has a 1 year low of $19.75 and a 1 year high of $42.00.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Recommended Story: The Discount Rate – What You Need to Know
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.